BioCryst reports second quarter 2015 financial results

BioCryst Pharmaceuticals, Inc. has announced financial results for the second quarter ended 30 June 2015.

“During the second quarter, we continued to make steady progress in executing our strategy and advancing our programs in order to bring forward an attractive oral prophylactic treatment for HAE and to change the lives of HAE patients,” said Jon P. Stonehouse, President & CEO of BioCryst.

The OPuS-2 (Oral ProphylaxiS-2) clinical trial is proceeding as planned, and BioCryst expects to report results at the end of 2015. OPuS-2 is a 12-week, randomized, three-arm, parallel cohort trial. This study evaluates the efficacy and safety of two doses of avoralstat, 300 mg and 500mg, administered three-times daily compared with placebo. Approximately 100 HAE patients will be enrolled in the U.S. and other select countries.

(Source: BioCryst)

2017-05-31T19:25:13+00:00